GlassScriptPhysician profile
Obaid S Malik
NPI 1972946077
$9,715.19
in general payments reported to CMS, 2019-2025
40 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,956 · 2020: $797 · 2021: $2,739 · 2022: $1,128 · 2023: $611 · 2024: $878 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,273.97 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $1,304.56 | 2021 | |
| Abbott Laboratories | $1,109.58 | 2019-2025 | Infinity, Proclaim, Eterna |
| Nevro Corp. | $705.24 | 2019-2023 | Senza |
| Medtronic, INC. | $636.16 | 2021-2024 | Intellis Adaptivestim, Percept PC Brainsense, Activa PC |
| Boston Scientific Corporation | $418.18 | 2021-2025 | Wavewriter Alpha Prime 16, Vercise |
| Collegium Pharmaceutical, INC. | $310.65 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $246.08 | 2019-2024 | Ztlido |
| Vertos Medical, INC. | $225.59 | 2019 | |
| Acadia Pharmaceuticals INC | $210.28 | 2023-2025 | Nuplazid |
| Mml US, INC. | $192.88 | 2023-2024 | Reactiv8 |
| Teva Pharmaceuticals USA, INC. | $181.00 | 2019-2025 | Austedo Xr, Austedo Xr |
| Stimwave Technologies Incorporated | $163.20 | 2022 | |
| Abbvie INC. | $127.66 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $127.20 | 2022-2025 | Ingrezza, Ongentys |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obaid Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.